E A Kowaluk
Overview
Explore the profile of E A Kowaluk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
635
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kowaluk E
Expert Opin Investig Drugs
. 2005 Jul;
7(4):535-43.
PMID: 15991991
Adenosine (ADO) is an endogenous purine nucleoside that functions as an extracellular signalling molecule. It is released locally at sites of cellular trauma, and acts on specific cell-surface purinergic receptors...
2.
Zheng G, Lee C, Pratt J, Perner R, Jiang M, Gomtsyan A, et al.
Bioorg Med Chem Lett
. 2001 Aug;
11(16):2071-4.
PMID: 11514141
A novel series of pyridopyrimidine analogues 9 was identified as potent adenosine kinase inhibitors based on the SAR and computational studies. Substitution of the C7 position of the pyridopyrimidino core...
3.
Zhu C, Mikusa J, Chu K, Cowart M, Kowaluk E, Jarvis M, et al.
Brain Res
. 2001 Jun;
905(1-2):104-10.
PMID: 11423084
Extracellular levels of adenosine (ADO) can be raised through inhibition of adenosine kinase (AK), a primary metabolic enzyme for ADO. AK inhibitors have shown antinociceptive activity in a variety of...
4.
Lee C, Jiang M, Cowart M, Gfesser G, Perner R, Kim K, et al.
J Med Chem
. 2001 Jun;
44(13):2133-8.
PMID: 11405650
Adenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation. Inhibition of adenosine kinase (AK), the primary metabolic enzyme for ADO,...
5.
Suzuki R, Stanfa L, Kowaluk E, Williams M, Jarvis M, Dickenson A
Br J Pharmacol
. 2001 Mar;
132(7):1615-23.
PMID: 11264257
1. Adenosine (ADO) receptor activation modulates sensory transmission in the dorsal horn. Little is known about the circumstances underlying release of the purine. The present study was conducted to investigate...
6.
McGaraughty S, Chu K, Wismer C, Mikusa J, Zhu C, Cowart M, et al.
J Pharmacol Exp Ther
. 2001 Feb;
296(2):501-9.
PMID: 11160637
The present study investigated 1) antihyperalgesic actions of a novel and selective adenosine kinase (AK) inhibitor, A-134974 (IC(50) = 60 pM), in the carrageenan model of thermal hyperalgesia; 2) effects...
7.
Boyle D, Kowaluk E, Jarvis M, Lee C, Bhagwat S, Williams M, et al.
J Pharmacol Exp Ther
. 2001 Feb;
296(2):495-500.
PMID: 11160636
Adenosine (ADO) is a homeostatic inhibitory autocoid that is released at sites of inflammation and tissue injury, and exerts anti-inflammatory effects via multiple interactions at ADO receptor subtypes. Inhibition of...
8.
Jarvis M, Wismer C, Schweitzer E, Yu H, van Biesen T , Lynch K, et al.
Br J Pharmacol
. 2001 Jan;
132(1):259-69.
PMID: 11156585
1. Exogenous ATP produces acute and localized pain in humans, and P2X receptor agonists elicit acute nociceptive behaviours in rodents following intradermal administration to the hindpaw. The predominant localization of...
9.
Cowart M, Lee C, Gfesser G, Bayburt E, Bhagwat S, Stewart A, et al.
Bioorg Med Chem Lett
. 2001 Jan;
11(1):83-6.
PMID: 11140740
The synthesis and SAR of a novel series of non-nucleoside pyridopyrimidine inhibitors of the enzyme adenosine kinase (AK) are described. It was found that pyridopyrimidines with a broad range of...
10.
Hajduk P, Gomtsyan A, DiDomenico S, Cowart M, Bayburt E, Solomon L, et al.
J Med Chem
. 2000 Dec;
43(25):4781-6.
PMID: 11123986
A strategy is described for designing high-affinity ligands using information derived from the NMR-based screening of fragments. The method involves the fragmentation of an existing lead molecule, identification of suitable...